NexgenRx Inc.
NEGXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | -0.03 | 8.63 | 0.08 |
| FCF Yield | 4.08% | 5.68% | 14.89% | 5.35% |
| EV / EBITDA | 8.27 | 16.19 | 1.50 | 2.46 |
| Quality | ||||
| ROIC | 8.79% | -1.91% | -0.14% | 42.40% |
| Gross Margin | 79.65% | 78.14% | 68.16% | 71.47% |
| Cash Conversion Ratio | 1.87 | -3.85 | -151.73 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.75% | 5.25% | 6.16% | 7.42% |
| Free Cash Flow Growth | -19.09% | -64.11% | 75.21% | 181.76% |
| Safety | ||||
| Net Debt / EBITDA | -0.50 | -1.37 | -9.97 | -4.60 |
| Interest Coverage | 38.58 | -3.75 | 0.52 | 11.32 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 2,961,538.26 | 1,429,695,177,215,189.80 |
| Cash Conversion Cycle | -35.48 | -122.13 | -97.81 | -175.39 |